| [1] |
Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology,2019,156(5):1368-1380. e10.
|
| [2] |
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2021,74(2):1014-1048.
|
| [3] |
Han J, Wei FL, Wu HX, et al. Clinical evaluation of droplet digital PCR for suspected ascites infection in patients with liver cirrhosis[J]. Hepatol Int,2024,18(4):1249-1260.
|
| [4] |
郭璐瑶, 侯维, 韩洁, 等. 高载量腹水细菌DNA水平对肝硬化患者发生自发性细菌性腹膜炎及不良预后的预测价值[J/OL]. 中华实验和临床感染病杂志(电子版),2025,19(3):146-156.
|
| [5] |
Chaves F, Garnacho-Montero J, Del Pozo JL, et al. Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)[J]. Med Intensiva (Engl Ed),2018,42(1):5-36.
|
| [6] |
Pianucci K, Cipriano F, Chung E. Review of urinary tract infections and pyelonephritis[J]. Pediatr Ann,2024,53(6):e217-e222.
|
| [7] |
Dubourg G, Abat C, Rolain JM, et al. Correlation between sputum and bronchoalveolar lavage fluid cultures[J]. J Clin Microbiol,2015,53(3):994-996.
|
| [8] |
杨永忠, 郭春平, 张兰英. 某院失代偿期肝硬化患者并发肺部感染的病原菌分布及其耐药性分析[J]. 抗感染药学,2024,21(11):1176-1179.
|
| [9] |
Falchi AG, Mascolo C, Sepe V, et al. Hyponatremia as a predictor of outcome and mortality: results from a second-level urban emergency department population[J]. Ir J Med Sci,2023,192(1):389-393.
|
| [10] |
Kim MY, Jeong WK, Baik SK. Application of ultrasound for the diagnosis of cirrhosis/portal hypertension[J]. J Med Ultrason (2001),2022,49(3):321-331.
|
| [11] |
Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT)[J]. Eur Respir J,2017,50(3):1700582.
|
| [12] |
Piekiełko P, Hareza DA, Stawowczyk E, et al. Empiric and targeted antibiotic therapy for bloodstream infections in internal medicine patients in Poland: a three-year analysis in a single centre using the AWaRe classification[J]. Pharmacol Rep,2025,77(4):1100-1108.
|
| [13] |
Popoiag RE, Fierbințeanu-Braticevici C. Spontaneous bacterial peritonitis: update on diagnosis and treatment[J]. Rom J Intern Med,2021,59(4):345-350.
|
| [14] |
Rhee C, Chen T, Kadri SS, et al. Trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis in US hospitals[J]. JAMA Netw Open,2024,7(6):e2418923.
|
| [15] |
Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond[J]. Gut,2012,61(2):297-310.
|
| [16] |
Wolf MF, Simon A. The use of piperacillin-tazobactam in neonatal and paediatric patients[J]. Expert Opin Drug Metab Toxicol,2009,5(1):57-69.
|
| [17] |
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)[J]. Clin Infect Dis,2022,75(2):187-212.
|
| [18] |
Yu Z, Zhao Y, Jin J, et al. Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study[J]. Int J Infect Dis,2022,120:59-64.
|
| [19] |
中华医学会肝病学分会. 肝硬化临床诊治管理指南(2025版)[J]. 中华肝脏病杂志,2025,33(10):958-976.
|
| [20] |
李雅欣, 丁惠国. 人血白蛋白在肝硬化及其并发症中的应用[J]. 临床肝胆病杂志,2025,41(3):409-414.
|
| [21] |
Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome[J]. N Engl J Med,2021,384(9):818-828.
|
| [22] |
中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 中华肝脏病杂志,2017,25(9):664-677.
|
| [23] |
Heybe MA, Mehta KJ. Role of albumin infusion in cirrhosis-associated complications[J]. Clin Exp Med,2024,24(1):58.
|
| [24] |
Tan W, Wang J, Shi PM, et al. Effects of low-dose and high-dose rifaximin in the treatment of covert hepatic encephalopathy[J]. J Clin Transl Hepatol,2022,10(6):1099-1106.
|
| [25] |
Faust N, Yamada A, Haider H, et al. Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis[J]. World J Hepatol,2020,12(5):239-252.
|
| [26] |
Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol,2013,58(5):911-921.
|
| [27] |
Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure[J]. J Hepatol,2016,64(3):574-582.
|
| [28] |
刘尚伟, 李兴红. 益生菌对肝硬化患者肠道菌群和肠道屏障功能的影响[J]. 中国微生态学杂志,2021,33(3):326-330.
|
| [29] |
Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant Gram-negative infections[J]. Clin Infect Dis,2024:ciae403.
|
| [30] |
Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections[J]. Lancet,2025,405(10474):257-272.
|
| [31] |
Kulkarni AV, Ravikumar ST, Tevethia H, et al. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study[J]. Sci Rep,2022,12(1):5503.
|
| [32] |
Solà E, Guevara M, Ginès P. Current treatment strategies for hepatorenal syndrome[J]. Clin Liver Dis (Hoboken),2013,2(3):136-139.
|
| [33] |
Karvellas CJ, Bajaj JS, Kamath PS, et al. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis[J]. Hepatology,2024,79(6):1463-1502.
|
| [34] |
Runyon BA. Management of adult patients with ascites due to cirrhosis: an update[J]. Hepatology,2009,49(6):2087-2107.
|
| [35] |
Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in chronic liver disease: an update[J]. J Clin Exp Hepatol,2022,12(3):937-947.
|